Evidence map›Paper›PMID 37368990›Full record

ArticleDiabetes2023

β-Cell Glucose Sensitivity to Assess Changes in β-Cell Function in Recent-Onset Stage 3 Type 1 Diabetes.

Stephen E Gitelman, Carmella Evans-Molina, Annamaria Guolo, Andrea Mari, Ele Ferrannini

Open access · bronzeAbstract read
In one paragraph

Article in Diabetes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

Stephen E GitelmanDepartment of Pediatrics and Diabetes Center, University of California, San Francisco, San Francisco, CA.ORCID 0000-0003-4186-4107
Carmella Evans-MolinaCenter for Diabetes and Metabolic Diseases, Indiana University School of Medicine, and Richard L. Roudebush Veterans' Administration Medical Center, Indianapolis, IN.ORCID 0000-0001-7764-8663
Annamaria GuoloDepartment of Statistical Sciences, University of Padua, Padua, Italy.
Andrea MariCNR Institute of Neuroscience, Padua, Italy.ORCID 0000-0002-1436-5591
Ele FerranniniCNR Institute of Clinical Physiology, Pisa, Italy.ORCID 0000-0002-1384-1584
Istituto di Fisiologia Clinica · ITNeuroscience Institute · ITRichard L. Roudebush VA Medical Center · USUniversity of California, San Francisco · USUniversity of Padua · IT

Funding

Translation CoreP30DK097512 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Carmella Evans-Molina · 2015 to 2026
$17.4M
Control of beta cell function and survival by RYR2-mediated calcium signalsR01DK127236 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI EVANS-MOLINA, CARMELLA · 2021 to 2025
$2.2M
β cell miRNAs Function as Molecular Hubs of Type 1 Diabetes PathogenesisR01DK127308 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI EVANS-MOLINA, CARMELLA · 2021 to 2024
$1.7M
Modeling Islet Dysfunction During Type 1 Diabetes ProgressionR21DK119800 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI EVANS-MOLINA, CARMELLA, FERRANNINI, ELEUTERIO · 2019 to 2020
$385k
BLRD VA I01 BX001733NIDDK NIH HHS P30 DK097512NIDDK NIH HHS R01 DK127236NIDDK NIH HHS R01 DK127308NIDDK NIH HHS R21 DK119800NIH HHS R21 DK119800-01A1
6 · The paper itself

Abstract

Following a diagnosis of type 1 diabetes (T1D), persisting C-peptide secretion leads to improved glycemic control and outcomes. Residual β-cell function is often assessed with serial mixed-meal tolerance tests, but these tests do not correlate well with clinical outcomes. Herein, we instead use β-cell glucose sensitivity (βGS) to assess changes in β-cell function, incorporating insulin secretion for a given serum glucose into the assessment of β-cell function. We evaluated changes in βGS in individuals enrolled in the placebo arm of 10 T1D trials performed at diabetes onset. We found that βGS showed a more rapid decline in children, as compared with adolescents and adults. Individuals in the top quartile of βGS baseline distribution had a slower rate in loss of glycemic control time over time. Notably, half of this group were children and adolescents. Finally, to identify predictors of glycemic control throughout follow-up, we ran multivariate Cox models and found that incorporating βGS significantly improved the overall model. Taken together, these data suggest that βGS may be of great utility in predicting those more likely to have a more robust clinical remission and may be of use in design of new-onset diabetes clinical trials and in evaluating response to therapies. ARTICLE HIGHLIGHTS: We undertook this study to better predict β-cell loss following type 1 diabetes diagnosis. We set out to answer whether β-cell glucose sensitivity (βGS) improves means to evaluate β-cell function postdiagnosis and whether βGS correlates with clinical outcomes. We found that βGS declines faster in children, subjects in the top baseline quartile of βGS exhibit slower β-cell decline (half are children), and incorporating βGS into multivariate Cox models for glycemic improves the model. The implications of our findings are that βGS predicts those likely to have robust clinical remissions and may help with clinical trials design.

Indexed as

Diabetes Mellitus, Type 1Insulin-Secreting CellsAdolescentAdultBlood GlucoseChildGlucoseHumansInsulinInsulin SecretionBlood GlucoseGlucoseInsulin

Identifiers

PMID37368990
PMCPMC10450822
OpenAlexW4382198728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.